The Belgian Chapter in the Merger Control Review- 12th Edition

The Belgian Chapter in the Merger Control Review- 12th Edition
September 2, 2021

Check whether your merger or acquisition needs prior clearance from competition authorities. Our experts Carmen Verdonck and Nina Methens give an overview of the Belgian merger control rules, the recent trends and developments in merger control and an outlook in “The Merger control Review”.

Click here to read the full chapter.

More information about the book is available here.

Written by

  • Carmen Verdonck

    Partner

  • Nina Methens

    Associate

Recommended articles

February 08, 2023

Brussels Court of Appeal rejects Carrefour’s request to suspend the Belgian Competition Authority’s decision authorising the concentration between Intermarché AB and Mestdagh, including Carrefour’s ‘gun-jumping’ argument

On 23 December 2022, the Brussels Court of Appeal (“Market Court”) rejected Carrefour Belgium’s application for the suspension of the Belgian Competition Authority’s (“BCA”) decision of 9 November 2022 authorising the concentration between Intermarché AB (“ITM”) and Mestdagh. On 9 November 2022, the BCA had cleared the concentration between ITM and Mestdagh in the first […]

Read on
January 30, 2023

The Belgian Competition Authority fines Novartis for abuse of collective dominance regarding eye disease medicines

The Belgian Competition Authority fines Novartis for abuse of collective dominance regarding eye disease medicines On 23 January 2018, the European Court of Justice (“ECJ”) handed down its judgment (C-179/16) in relation to Novartis’ Lucentis® and Roche’s Avastin® eye disease medicines, and ruled that disseminating misleading information on the off-label use of a medicine could constitute a restriction of competition ‘by object’. Exactly 5 years later, on 23 January 2023, the Belgian Competition Authority (“BCA”) imposed a fine on Novartis Pharma SA and Novartis AG (together “Novartis”) for abuse of collective dominance resulting from disseminating misleading information regarding risks in relation to the off label use of Roche’s Avastin®.

Read on
June 29, 2022

Belgium takes important step in introducing Foreign Direct Investment screening

On 1 June 2022, Belgium’s Federal and various Regional governments entered into a draft cooperation agreement to introduce a mechanism for screening Foreign Direct Investments (“FDI”).

Read on